Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects

Small intestinal bacterial overgrowth (SIBO) can partly explain irritable bowel syndrome (IBS), and rifaximin has been observed to improve abdominal symptoms in nonconstipated IBS patients. However, there are few reports on the association of the rifaximin treatment periods with the results of a lac...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Suhyun, Lee, Kwang Jae, Kim, Young-Sang, Kim, Kyu-Nam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444477/
https://www.ncbi.nlm.nih.gov/pubmed/26028929
http://dx.doi.org/10.3346/jkms.2015.30.6.757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4444477/
https://www.ncbi.nlm.nih.gov/pubmed/26028929
http://dx.doi.org/10.3346/jkms.2015.30.6.757

Ejemplares similares